首页> 外文期刊>Digestive diseases >Role of Immunosuppressives in Special Situations: Perianal Disease and Postoperative Period
【24h】

Role of Immunosuppressives in Special Situations: Perianal Disease and Postoperative Period

机译:免疫抑制剂在特殊情况下的作用:肛周疾病和术后时期

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Complex perianal disease is associated with poor outcome and requires early effective therapy. Corticosteroids are not effective in perianal fistulising Crohn's disease, and antibiotics, immunosuppressants and anti-TNF therapy are required. It is important to consider combined medical surgical therapy after accurate imaging using an MRI scan of the pelvis. Drainage of any abscess at examination under anaesthesia and seton insertion are important before introduction of immunosuppressants and anti-TNF therapy. Long-term follow up of patients in a single centre reported responders to azathioprine having a reduced risk of perianal surgery (OR = 0.36; 95% CI: 0.27-0.46), but complex perianal fistulising Crohn's disease generally requires combination therapy with anti-TNF and azathioprine. Patients with recent perianal disease without fistulae and aged 40 years or older respond better to azathioprine monotherapy. Response to monotherapy with azathioprine is often slow and incomplete. In the recent GETAID study of early administration of azathioprine versus conventional management in patients at high risk of disabling disease, a higher cumulative proportion of patients in the azathioprine group were free of perianal surgery. In patients not responding to anti-TNF therapy, thalidomide or tacrolimus may be considered. Hyperbaric oxygen may be used as adjunctive therapy where available. The role of adipose-derived stem cell injection requires further long-term studies. In prevention of post-operative recurrence of Crohn's disease, azathioprine or 6-mercaptopurine had a favourable incremental cost-effectiveness ratio compared with no prophylactic therapy up to 1 year. In a Cochrane systematic review, azathioprine/6-mercaptopurine was associated with a significantly reduced risk of clinical recurrence [RR = 0.59, 95% CI: 0.38-0.92, number needed to treat (NNT) = 7] and severe endoscopic recurrence (RR = 0.6, 95% CI: 0.44-0.92, NNT = 4). Individual studies of prevention of post-operative recurrence using azathioprine/6-mercaptopurine have shown only modest benefit. In patients at high risk of relapse after surgical resection, anti-TNF therapy may be beneficial, but more data is required from ongoing studies. Strategies to prevent post-operative recurrence in Crohn's disease are evolving but need further refinement. (C) 2014 S. Karger AG, Basel
机译:复杂的肛周疾病与预后不良有关,需要早期有效的治疗。皮质类固醇对肛周瘘管克罗恩病无效,因此需要抗生素,免疫抑制剂和抗TNF治疗。重要的是,在使用骨盆的MRI扫描进行精确成像后,考虑进行联合外科手术治疗。在引入免疫抑制剂和抗TNF治疗之前,在麻醉和seton插入的情况下排出脓肿非常重要。在一个中心进行的患者的长期随访报告说,对硫唑嘌呤的反应者的肛周手术风险降低(OR = 0.36; 95%CI:0.27-0.46),但是复杂的肛周瘘管克罗恩病通常需要联合抗TNF治疗和硫唑嘌呤。患有肛周疾病且无瘘管且年龄在40岁或40岁以上的患者对硫唑嘌呤单一疗法的反应更好。硫唑嘌呤对单药治疗的反应通常缓慢且不完全。在最近的GETAID研究中,在易患疾病的高风险患者中早期给予硫唑嘌呤与常规治疗相比,硫唑嘌呤组中较高比例的患者无肛周手术。对于抗TNF治疗无反应的患者,可以考虑沙利度胺或他克莫司。高压氧可在可用时用作辅助治疗。脂肪干细胞注射的作用需要进一步的长期研究。为了预防克罗恩氏病的术后复发,与长达一年的无预防性治疗相比,硫唑嘌呤或6-巯基嘌呤的成本效益比具有良好的增量。在Cochrane的系统评价中,硫唑嘌呤/ 6-巯基嘌呤与临床复发风险显着降低[RR = 0.59,95%CI:0.38-0.92,需要治疗的数目(NNT)= 7]和严重的内镜复发(RR = 0.6,95%CI:0.44-0.92,NNT = 4)。单独使用硫唑嘌呤/ 6-巯基嘌呤预防术后复发的研究仅显示了中度获益。对于手术切除后复发风险较高的患者,抗TNF治疗可能是有益的,但正在进行的研究需要更多数据。防止克罗恩病术后复发的策略正在发展,但需要进一步完善。 (C)2014 S.Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号